Trial Profile
A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 21 Dec 2023
Price :
$35
*
At a glance
- Drugs Tazemetostat (Primary) ; Cyclophosphamide; Doxorubicin; Prednisolone; Rituximab; Vincristine
- Indications Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms A a Lysa A Study; Epi-RCHOP
- 18 Dec 2023 Results assessing Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial published in the Journal of Clinical Oncology
- 12 Dec 2023 Results (As of June 14, 2022,n=62)presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 12 Dec 2023 Results (From July 31, 2020 to July 18, 2022, n=122) assessing safety and efficacy of Tazemetostat in Combination with R-CHOP in Elderly Newly Diagnosed Diffuse Large B Cell Lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition